The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...

Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991. View on euronews ...